DIVERGENT HTA DECISIONS IN EUROPE FOR ONCOLOGY DRUGS GRANTED BREAKTHROUGH DESIGNATION

被引：0
|
作者：
Borissov, B. [1 ]
机构：
[1] Prescriptia EOOD, Sofia, Bulgaria
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.353
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN232
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [1] Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
    Puthumana, Jeremy
    Wallach, Joshua D.
    Ross, Joseph S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (03): : 301 - 303
  • [2] HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe
    Bento, G.
    Dumoulin, O.
    Reinert, M.
    Gulotta, G.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S336 - S336
  • [3] Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017–2019
    Atasi Poddar
    Miranda Raggio
    John Concato
    [J]. Therapeutic Innovation & Regulatory Science, 2024, 58 : 214 - 221
  • [4] Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017-2019
    Poddar, Atasi
    Raggio, Miranda
    Concato, John
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (01) : 214 - 221
  • [5] INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ORPHAN AND NON-ORPHAN ONCOLOGY DRUGS
    Achour, L.
    Hanna, E.
    Borissov, B. N.
    Ma, F.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S23 - S23
  • [6] Developing Standards for Breakthrough Therapy Designation in Oncology
    Horning, Sandra J.
    Haber, Daniel A.
    Selig, Wendy K. D.
    Ivy, S. Percy
    Roberts, Samantha A.
    Allen, Jeff D.
    Sigal, Ellen V.
    Sawyers, Charles L.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4297 - 4304
  • [7] INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ONCOLOGY PRODUCTS
    Dabbous, M.
    Achour, L.
    Chachoua, L.
    Hanna, E.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S5 - S5
  • [8] PROS IN ONCOLOGY HTA DECISIONS, DO THEY MATTER?
    Hintzen, C. L.
    Lie, X.
    van Engen, A.
    New, M. J.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A470 - A471
  • [9] DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME?
    Cai, J.
    Wang, T.
    McAuslane, N.
    Liberti, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S809 - S809
  • [10] CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY - AN ANALYSIS USING THE PRISMACCESS® DATABASE
    Mayer, F.
    Hodek, J.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S63 - S64
12345